{"id":"W2586804150","doi":"10.1200/jco.2006.24.18_suppl.3506","title":"A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; Irinotecan; Capecitabine; Clinical endpoint; Bevacizumab; FOLFIRI; Celecoxib; Nausea; Placebo; Gastroenterology; Internal medicine; Bolus (digestion); Colorectal cancer; Tolerability; Vomiting; Randomized controlled trial; Chemotherapy; Adverse effect; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002162042,0.001601971,0.00295665,0.0004700613,0.000501347,0.001150091,0.001009466,0.001646089,0.006884397],"category_scores_gemma":[0.00195671,0.0008209473,0.001560747,0.0004769605,0.001347604,0.0007280344,0.0005146754,0.002769788,0.0009653451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001120317,"about_ca_system_score_gemma":0.00213624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001893377,"about_ca_topic_score_gemma":0.004041274,"domain_scores_codex":[0.9990975,0.0005233887,0.00004875498,0.000141894,0.00005849409,0.0001300382],"domain_scores_gemma":[0.9987062,0.0003140326,0.000269116,0.00009143445,0.00008007009,0.0005391693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9884579,0.004804981,0.0002841305,0.0001586928,0.0002919055,0.00002180692,0.00002002503,0.0001514763,0.001606635,0.00003317335,0.0003005911,0.003868723],"study_design_scores_gemma":[0.9498453,0.04874757,0.0006264232,0.000008192897,0.0001843292,0.00001500699,0.000006002249,0.0001566496,0.0001846091,0.00002330634,0.0001975021,0.00000507305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923697,0.001674391,0.0002913461,0.0004518343,0.0003719674,0.003060277,0.0005626766,0.00007934467,0.001138471],"genre_scores_gemma":[0.9901432,0.001149748,0.001199488,0.0008644458,0.0004757697,0.003209444,0.0008931672,0.0000182691,0.002046534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006884397,"threshold_uncertainty_score":0.02303058,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1089623824251588,"score_gpt":0.4604463677779143,"score_spread":0.3514839853527555,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}